Drug Discovery Informatics Market Size, Share & Trends Analysis Report By Workflow (Discovery, Development), By Mode (In-house, Outsourced), By Services, By Region, Vendor Landscape, And Segment Forecasts, 2018 - 2025

Industry Outlook

The global drug discovery informatics market size was estimated at USD 713.4 million in 2016. It is anticipated to progress at a CAGR of 12.6% over the forecast period. Introduction of in silico tools, which enable computation with varied workflows that are in sync with rate of modern medicinal chemistry is one of the key trends stimulating market growth. Drug discovery is a functional process in pharmaceutical and biotechnology companies. It involves different steps and procedures that depend on in-silico tools for reducing the complexity of a process.

Identification of lead molecules requires synthesis and analysis of many derivatives that can be prepared with the help of in silico modeling tools. Success of a drug discovery experiment depends extensively on effectiveness of tools employed to assess varied aspects of drugs. In silico tools used herein include modeling tools for determination of 3D structures of ligand and protein-ADMET assessment-affinity estimation in docking and drug-ligand interaction for pharmacological profiling.

Major market participants are involved in adoption of in silico modeling tools, which is expected to work in favor of the market. In silico tools are promising tools that provide valuable structural screening and information validation at a fraction of the cost of traditional methods, shortening the discovery process to a great extent.

Migration from expensive and large mainframe computers as well as shared clusters to personal supercomputers, powerful desktops, small workgroup clusters, or laptops is extending the full potential of next-generation discovery information processing provided to a broader range of scientists. The onus is shifting to software developers, who need to create scientific software products that are easy to use, in order to most effectively exploit the power of inexpensive computing.

Advancements with respect to fundamental algorithms employed by computational information processing for predictive chemistry, which lead to improvement in scientific innovation and laboratory informatics, are likely to augment the market in the coming years. This group of “front-line” scientific applications, part of a category of software generally referred to as “laboratory informatics,” is a critical component in the redefinition of discovery information processing and is increasingly being used by laboratory chemists and biologists.

Workflow Insights

Presence of some software and tools for protein structure prediction, reverse docking, conformational analysis, microarray analysis, pharmacophore mapping, comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) coupled with introduction of novel tools is projected to drive adoption of lead generation informatics over the coming years.

Development information processing comprises lead optimization, FHD preparation, Phase IA, and Phase IB informatics. Leads generated in prior steps of drug discovery is optimized in this step. It involves testing and screening of different chemical agents to check their biological effects on a given target of interest. It employs chemical libraries, combinatorial chemistry, and high throughput screening for this purpose.

Mode Insights

Presence of different co-operation models, such as joint ventures, strategic partnership, price competition, and project selection, for outsourcing drug information processing solutions in the industry are poised to support the growth of the drug discovery informatics market. Furthermore, other benefits associated include compressed timelines, increased production, focus on core competencies, minimized risks, and access to novel technologies.

In-house informatics includes companies that are involved in drug discovery with use of their own technology platforms. Companies operating in this segment are influencing the dynamics of the segment. Some of the key companies are Certara, Inc.; Boehringer Ingelheim GmbH, and ChemAxon.

Service Insights

Reduction in price will greatly rev up the adoption rates of genome sequencing and is estimated to result in significant increase in its demand and market adoption. Initiatives taken to foster and disseminate molecular informatics are anticipated to contribute to the growth of the segment over the forecast period.

Informatics companies are providing software solutions such as biological entity management system, PBPK modeling and simulation, and pharmacometrics analysis. These companies include Certara; Infosys; Collaborative Drug Discovery; and Albany Molecular Research, Inc.

Regional Insights

North America dominated the market owing to higher incidence rates of different infectious diseases and oncology diseases. Simultaneous developments of next generation sequencing and chemical laboratories in the region are among the primary growth stimulants of the market for drug discovery informatics.

Asia Pacific provides a substantial cost saving advantage, with savings ranging from 50% to 80% of the cost as compared to developed nations, thus leading to an augmentation in the volume of clinical trials being conducted in this region. This is, thereby, providing a significant push to the regional market. The region is expected to experience the fastest growth during the regional market.

Drug Discovery Informatics Market Share Insights

Major participants include Albany Molecular Research Inc.; Certara; Boehringer Ingelheim GmBh; Charles River Laboratories; Infosys; GVK Biosciences; Collaborative Drug Discovery Inc.; DiscoverX; ChemAxon; Jubilant Biosys; Novo Informatics; and Selvita.

These players are embracing the trend of collaborating with research institutes and clinical research organizations to gain a competitive edge. Furthermore, they are also collaborating with the leading pharmaceutical manufacturers to consolidate their position in the arena.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at regional & country level and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the global drug discovery informatics market report on the basis of workflow, services, mode, and region:

• Workflow Outlook (Revenue, USD Million, 2014 - 2025)

  • Drug Discovery

    • Identification & Validation Informatics Assay Development Informatics

    • Lead Generation information processing

  • Drug Development

    • Lead Optimization

    • FHD Preparation

    • Phase IA

    • Phase IB/2

• Mode Outlook (Revenue, USD Million, 2014 - 2025)

  • In-house

  • Outsourced

• Service Outlook (Revenue, USD Million, 2014 - 2025)

  • Sequence Analysis Platforms

  • Molecular Modeling

  • Docking

  • Clinical Trial Data Management

  • Others

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

  • Middle East and Africa (MEA)

    • South Africa